Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 30287523

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2018 Dec 6
First author
Flinn IW

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2018 Dec 6;132(23):2422-2424. doi: 10.1182/blood-2018-10-879650.
    note
    Source null
    related pmid
    30523122
    relationship
    Comment in

Authors and identifiers

  1. name
    Flinn IW
    type
    Author
  2. name
    Hillmen P
    type
    Author
  3. name
    Montillo M
    type
    Author
  4. name
    Nagy Z
    type
    Author
  5. name
    Illés Á
    type
    Author
  6. name
    Etienne G
    type
    Author
  7. name
    Delgado J
    type
    Author
  8. name
    Kuss BJ
    type
    Author
  9. name
    Tam CS
    type
    Author
  10. name
    Gasztonyi Z
    type
    Author
  11. name
    Offner F
    type
    Author
  12. name
    Lunin S
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Flinn IW
    type
    Author
  2. name
    Hillmen P
    type
    Author
  3. name
    Montillo M
    type
    Author
  4. name
    Nagy Z
    type
    Author
  5. name
    Illés Á
    type
    Author
  6. name
    Etienne G
    type
    Author
  7. name
    Delgado J
    type
    Author
  8. name
    Kuss BJ
    type
    Author
  9. name
    Tam CS
    type
    Author
  10. name
    Gasztonyi Z
    type
    Author
  11. name
    Offner F
    type
    Author
  12. name
    Lunin S
    type
    Author
bibliography ids
  1. nci-bib-84d03022dad1d19be35c4c26
book metadata
content sha256
dfbdd10a405005b1e1304dd02d9d21eb5f859feabc52283123f6bd8794c0e015
document type
citation
dois
  1. 10.1182/blood-2018-05-850461
electronic publication date
display
2018 Oct 4
precision
day
year
2018
evidence scope
bibliographic_metadata_only
id
pubmed:30287523
immutable id
pubmed:30287523@dfbdd10a405005b1e1304dd02d9d21eb5f859feabc52283123f6bd8794c0e015
journal
abbreviation
Blood
issn electronic
1528-0020
issn print
0006-4971
issue
23
name
Blood
nlm unique id
7603509
pages
2446-2455
volume
132
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2018 Dec 6;132(23):2422-2424. doi: 10.1182/blood-2018-10-879650.
    note
    Source null
    related pmid
    30523122
    relationship
    Comment in
outcomes validated
false
pmid
30287523
provenance
batch id
438b2803888025c6cf56
provider
NCBI PubMed ESummary
record sha256
af1591c6f6c990b99f7010dae860dbdd18c605ed95d495a2c13fd77125871cc0
response sha256
0adf5ff07d3aa03a45feef5e4b7998e2ddea370eb9d1c6aa9134c5fd329767e6
retrieved at
2026-09-09T23:47:36.359220+00:00
publication date
display
2018 Dec 6
precision
day
year
2018
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/30287523/
title
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.

Preserved source evidence · Not medical advice